Nick Pizzie, the Chief Financial Officer of Axsome Therapeutics, Inc. (NASDAQ:AXSM), recently executed a series of stock transactions according to a Form 4 filing with the Securities and Exchange ...

Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), recently sold a substantial block of the company's ordinary shares. The ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...

A U.S. judge ordered federal agencies to restore access to health-related webpages and datasets removed by the Trump ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Shares of Axsome Therapeutics ( AXSM -0.49%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.